TY - JOUR
T1 - In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers
AU - Watanabe, Sumiyo
AU - Hayashi, Kotaro
AU - Toh, Kazuko
AU - Kim, Hyun Jin
AU - Liu, Xueying
AU - Chaya, Hiroyuki
AU - Fukushima, Shigeto
AU - Katsushima, Keisuke
AU - Kondo, Yutaka
AU - Uchida, Satoshi
AU - Ogura, Satomi
AU - Nomoto, Takahiro
AU - Takemoto, Hiroyasu
AU - Cabral, Horacio
AU - Kinoh, Hiroaki
AU - Tanaka, Hiroyoshi Y.
AU - Kano, Mitsunobu R.
AU - Matsumoto, Yu
AU - Fukuhara, Hiroshi
AU - Uchida, Shunya
AU - Nangaku, Masaomi
AU - Osada, Kensuke
AU - Nishiyama, Nobuhiro
AU - Miyata, Kanjiro
AU - Kataoka, Kazunori
N1 - Funding Information:
This research was financially supported by the Funding Program for World-Leading Innovative R&D in Science and Technology (FIRST, JSPS), Grants-in-Aid for Scientific Research of MEXT (JSPS KAKENHI Grant Numbers 24659411 to S.W., 25000006 to K.K., 25282141, and 17H02098 to K.M.), the Center of Innovation (COI) Program (JST), the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT, AMED), the Project for Cancer Research and Therapeutic Evolution (P-CREATE, AMED), the Basic Science and Platform Technology Program for Innovative Biological Medicine (IBIOMED, AMED), the Cooperative Research Program of “Network Joint Research Center for Materials and Devices: Dynamic Alliance for Open Innovation Bridging Human, Environment and Materials”, and a grant JSPS Core-to-Core Program, A. Advanced Research Networks. The authors are deeply grateful to Professor K. Tsumoto (UTokyo) for his support in the density measurements. The authors are also grateful to Ms. A. Miyoshi (UTokyo) for her technical assistance.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/4/24
Y1 - 2019/4/24
N2 - Stabilisation of fragile oligonucleotides, typically small interfering RNA (siRNA), is one of the most critical issues for oligonucleotide therapeutics. Many previous studies encapsulated oligonucleotides into ~100-nm nanoparticles. However, such nanoparticles inevitably accumulate in liver and spleen. Further, some intractable cancers, e.g., tumours in pancreas and brain, have inherent barrier characteristics preventing the penetration of such nanoparticles into tumour microenvironments. Herein, we report an alternative approach to cancer-targeted oligonucleotide delivery using a Y-shaped block catiomer (YBC) with precisely regulated chain length. Notably, the number of positive charges in YBC is adjusted to match that of negative charges in each oligonucleotide strand (i.e., 20). The YBC rendezvouses with a single oligonucleotide in the bloodstream to generate a dynamic ion-pair, termed unit polyion complex (uPIC). Owing to both significant longevity in the bloodstream and appreciably small size (~18 nm), the uPIC efficiently delivers oligonucleotides into pancreatic tumour and brain tumour models, exerting significant antitumour activity.
AB - Stabilisation of fragile oligonucleotides, typically small interfering RNA (siRNA), is one of the most critical issues for oligonucleotide therapeutics. Many previous studies encapsulated oligonucleotides into ~100-nm nanoparticles. However, such nanoparticles inevitably accumulate in liver and spleen. Further, some intractable cancers, e.g., tumours in pancreas and brain, have inherent barrier characteristics preventing the penetration of such nanoparticles into tumour microenvironments. Herein, we report an alternative approach to cancer-targeted oligonucleotide delivery using a Y-shaped block catiomer (YBC) with precisely regulated chain length. Notably, the number of positive charges in YBC is adjusted to match that of negative charges in each oligonucleotide strand (i.e., 20). The YBC rendezvouses with a single oligonucleotide in the bloodstream to generate a dynamic ion-pair, termed unit polyion complex (uPIC). Owing to both significant longevity in the bloodstream and appreciably small size (~18 nm), the uPIC efficiently delivers oligonucleotides into pancreatic tumour and brain tumour models, exerting significant antitumour activity.
KW - Animals
KW - Antineoplastic Agents/chemical synthesis
KW - Brain Neoplasms/genetics
KW - Carbocyanines/chemistry
KW - Cell Cycle Proteins/antagonists & inhibitors
KW - Cell Line, Tumor
KW - Drug Carriers/chemical synthesis
KW - Fluorescent Dyes/chemistry
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Injections, Intravenous
KW - Male
KW - Mice
KW - Nanostructures/administration & dosage
KW - Oligonucleotides/chemical synthesis
KW - Pancreatic Neoplasms/genetics
KW - Polyethylene Glycols/chemistry
KW - Polylysine/chemistry
KW - Protein-Serine-Threonine Kinases/antagonists & inhibitors
KW - Proto-Oncogene Proteins/antagonists & inhibitors
KW - RNA, Long Noncoding/antagonists & inhibitors
KW - RNA, Small Interfering/chemical synthesis
KW - Static Electricity
KW - Survival Analysis
KW - Xenograft Model Antitumor Assays
UR - http://www.scopus.com/inward/record.url?scp=85064893429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064893429&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-09856-w
DO - 10.1038/s41467-019-09856-w
M3 - Article
C2 - 31019193
AN - SCOPUS:85064893429
SN - 2041-1723
VL - 10
SP - 1894
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1894
ER -